Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovery, research and development of biologic drugs and novel oncology therapeutics. The Company’s lead investigational product candidate is oncology therapeutic XBIO-101, which is used for the treatment of progestin - resistant endometrial cancer. The Company is currently conducting a Phase 2 trial for XBIO-101. The Company’s lead proprietary technology is PolyXen, which enables platform technology that can be applied to protein or peptide therapeutics using the natural polymer polysialic acid. The Company’s technology includes XBIO-101, PolyXen, OncoHist, ErepoXen and ImuXen. ErepoXen or polysialylated erythropoietin is an internal drug candidate which uses the company’s PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.